KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $2.6 million.

  • Royalty Pharma's Treasury Shares fell 173.13% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 173.13%. This contributed to the annual value of $2.7 million for FY2024, which is 125.52% up from last year.
  • Royalty Pharma's Treasury Shares amounted to $20.5 million in Q3 2025, which was up 21088.87% from $21.5 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Treasury Shares ranged from a high of $21.5 million in Q2 2025 and a low of $3.1 million during Q2 2024
  • Its 3-year average for Treasury Shares is $10.4 million, with a median of $8.6 million in 2023.
  • As far as peak fluctuations go, Royalty Pharma's Treasury Shares surged by 2562.53% in 2021, and later tumbled by 630.79% in 2023.
  • Over the past 5 years, Royalty Pharma's Treasury Shares (Quarter) stood at $2.7 million in 2021, then grew by 3.35% to $2.8 million in 2022, then decreased by 6.31% to $2.6 million in 2023, then increased by 1.26% to $2.7 million in 2024, then decreased by 1.92% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.6 million for Q2 2025, and $2.7 million during Q1 2025.